August 2024 - Page 2 of 3 - BioMedWire (BMW)

TuesdayAug 20, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) CEO Discusses Findings of Buntanetap Phase 2/3 Alzheimer’s Study on the Bell2Bell Podcast

Annovis Bio’s lead drug candidate buntanetap has the potential to significantly improve the quality of life for early Alzheimer’s patients In a short-term Phase 2/3 study, buntanetap has been shown to work three times better than the standard of care in the market The company plans further clinical trials to validate the efficacy and safety of buntanetap in treating both Parkinson’s and Alzheimer’s diseases Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, presented significant data and findings of its Phase 2/3 Alzheimer’s study of lead drug candidate buntanetap at the Alzheimer’s Association…

MondayAug 19, 2024 1:30 pm

UCSF Team Tests New Drug That Could Reverse Multiple Sclerosis

Multiple sclerosis is an autoimmune condition that affects an individual’s brain and spinal cord, causing symptoms that include difficulty walking or problems with one’s vision or balance. The condition’s mechanism of action involves using an individual’s immune system to attack the myelin, a protein and fatty substance that protects and surrounds nerve fibers. By damaging myelin, nerves aren’t able to carry electrical impulses from and to the brain. This damage also allows scar tissue known as sclerosis to form. This chronic disease of the central nervous system may, in some cases, lead to severe disability. Now, researchers at Contineum Therapeutics…

FridayAug 16, 2024 10:00 am

Enrollment for Medicare Advantage Differs Sharply in California Counties

In America, Medicare Advantage is increasing in popularity among beneficiaries of Medicare. Insurers under this version of Medicare offer lower premiums, with dental and vision coverage added on. Jointly, more than 50% of eligible recipients of Medicare are on private plans. However, a recent report from KFF determined that there were huge differences between enrollment in Medicare Advantage in the northern and southern counties of California. Data from the Centers for Medicare & Medicaid Services shows that market penetration for Medicare Advantage was considerably lower in northern counties in comparison to southern counties. The state of California differs from other…

WednesdayAug 14, 2024 10:00 am

Studies Show Protein, Reelin, Protects Brain Against Alzheimer’s, Aging

Researchers conducting separate studies published last year all determined that reelin, a protein that helps maintain memory and thinking in the brain, may also protect this important organ from diseases of aging such as Alzheimer’s. The researchers also found that if levels of reelin decrease, the vulnerability of neurons increases. Professor Li-Huei Tsai of MIT stated that increasing evidence had shown that reelin acted as a protector of the brain. Tsai is also the director of the Picower Institute for Learning and Memory. The studies have inspired efforts to develop medications that help reelin function better or boost its levels…

WednesdayAug 14, 2024 9:45 am

Annovis Bio Inc. (NYSE: ANVS) Lead Compound Shows Synergistic Cognitive Enhancement

Annovis Bio’s lead compound, buntanetap, shows significant enhanced cognitive benefits when combined with GLP-1 agonist dulaglutide in a mouse model Buntanetap targets neurodegenerative conditions like Alzheimer’s and Parkinson’s diseases GLP-1 agonists, typically used for diabetes, weight loss, and heart conditions, have shown potential in addressing neuroinflammation and neurodegeneration The combination treatment results were compelling: While buntanetap alone restored cognitive function to 100% and dulaglutide alone to 80%, the combination restored and also enhanced cognitive function beyond levels seen in healthy controls Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company, announced new preclinical data demonstrating lead compound buntanetap’s potential…

MondayAug 12, 2024 10:30 am

Clene Inc.’s (NASDAQ: CLNN) Makes Significant Strides in Developing its Lead Agent, CNM-Au8(R), to Address Neurodegenerative Conditions

Clene has conducted five Phase 2 clinical trials, three with long-term extensions, and three expanded access programs (with additional studies ongoing) to evaluate the safety and efficacy of CNM-Au8 The global ALS treatment market is poised for growth, driven by an aging population and limited current treatment options CNM-Au8 works by improving cellular energy production and utilization, which is crucial for maintaining neuronal health, and is at a deficit in neurodegenerative diseases Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases,…

MondayAug 12, 2024 10:00 am

Antioxidants in Seaweed Could Help in Forestalling Parkinson’s Disease

Parkinson’s disease is a progressive condition that affects an individual’s nervous system and the body parts controlled by the nerves. Scientifically speaking, the disease is brought on by neuronal damage caused by too much production of reactive oxygen species. Damage mainly affects neurons that produce dopamine, which plays a role in cognitive function and motor control. The condition usually gets worse over time, with the first symptom often being a tremor in the hands. Other symptoms include painful muscle contractions, tremors, and difficulty speaking. As the population globally grows older, the number of individuals suffering from Parkinson’s continues to increase.…

MondayAug 12, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) Secures U.S. Patent Covering Methods For Treating TBI and Preventing Nerve Cell Death With Buntanetap

U.S. Patent No. 12,042,482 specifically addresses traumatic brain injury (“TBI”) treatment with buntanetap, enhancing Annovis Bio’s portfolio that includes various patents and applications for using buntanetap in treating both acute and chronic neurodegenerative diseases and mental illnesses Buntanetap targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins such as amyloid beta, tau, alpha-synuclein, and TDP43 TBI is one of the major causes of death and disability in the US with annual death rate exceeding 70,000 Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company, announced the issuance of a U.S. patent for treating traumatic brain injury (“TBI”) with…

FridayAug 09, 2024 10:00 am

Australia Launches Novel Immunotherapy Program to Help Babies with Peanut Allergies

Australia recently launched a countrywide immunotherapy program for infants with peanut allergies. The program is a partnership between the Murdoch Children’s Research Institute and the country’s National Allergy Center of Excellence. This is the first time a countrywide program for peanut allergies is being integrated into mainstream care globally. The program, whose objective is to safely build tolerance and hopefully achieve remission, is available for babies under 12 months who have been diagnosed with peanut allergies. The infants must be under the care of an allergy specialist in one of the 10 public pediatric hospitals across the states taking part…

FridayAug 09, 2024 9:45 am

Astiva Health Inc. Focused on Establishing Lifelong Relationships, Providing Tailored Healthcare Approach to Underserved Populations

Survey indicates sizable proportion of older adult population copes with healthcare costs by skipping treatments, cutting back on basic and essential needs Astiva Health is keenly aware of problems faced by underserved senior population The company strives to bridge healthcare gaps through proactive, culturally responsive solutions As growing numbers of the U.S. population reach age 65, the challenge of adequate healthcare becomes even more critical. In fact, a West Health-Gallup survey reports that some elderly are forgoing needed care because of healthcare costs (https://ibn.fm/pJGqA). Astiva Health, a dynamic and innovative Medicare Advantage Prescription Drug (“MAPD”) health plan, is on a mission…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Month: August 2024

Annovis Bio Inc. (NYSE: ANVS) CEO Discusses Findings of Buntanetap Phase 2/3 Alzheimer’s Study on the Bell2Bell Podcast

UCSF Team Tests New Drug That Could Reverse Multiple Sclerosis

Enrollment for Medicare Advantage Differs Sharply in California Counties

Studies Show Protein, Reelin, Protects Brain Against Alzheimer’s, Aging

Annovis Bio Inc. (NYSE: ANVS) Lead Compound Shows Synergistic Cognitive Enhancement

Clene Inc.’s (NASDAQ: CLNN) Makes Significant Strides in Developing its Lead Agent, CNM-Au8(R), to Address Neurodegenerative Conditions

Antioxidants in Seaweed Could Help in Forestalling Parkinson’s Disease

Annovis Bio Inc. (NYSE: ANVS) Secures U.S. Patent Covering Methods For Treating TBI and Preventing Nerve Cell Death With Buntanetap

Australia Launches Novel Immunotherapy Program to Help Babies with Peanut Allergies

Astiva Health Inc. Focused on Establishing Lifelong Relationships, Providing Tailored Healthcare Approach to Underserved Populations

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search